Actively Recruiting
Phase 1 Study of Anti-CEA CAR-T Cell Therapy for Patients With Colorectal Cancer Liver Metastases After Surgery Evaluating Safety, Effectiveness, and Dosage in Patients With Minimal Residual Disease
Led by Changhai Hospital · Updated on 2022-03-11
18
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the safety and effectiveness of anti-CEA CAR-T cell therapy in patients with colorectal cancer who have liver metastases and have undergone complete tumor removal surgery R0 resection. This phase I clinical trial focuses on patients with minimal residual disease detected by positive circulating tumor DNA ctDNA, which may lead to recurrence. The study builds on promising preclinical results showing good safety and potential effects of anti-CEA CAR-T cells targeting tumors expressing carcinoembryonic antigen CEA. Participants will receive intravenous infusions of anti-CEA CAR-T cells at varying doses 1x106kg, 3x106kg, and 6x106kg using a standard dose-escalation design to determine the maximum tolerated dose. The study includes patients with positive minimal residual disease after surgery and adjuvant chemotherapy, without visible tumors on imaging. The trial will evaluate safety, treatment impact on minimal residual disease, and recurrence-free survival over a two-year period post-infusion. During the study, participants will be closely monitored for adverse events within 28 days after CAR-T cell infusion. Researchers will assess minimal residual disease status and recurrence-free survival for up to two years following treatment. Pharmacokinetics of the infused cells will also be studied over this period. Participants will undergo regular evaluations including imaging and laboratory tests to track treatment effects and safety throughout the trial.
CONDITIONS
Brief Title
Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here